ible assets 51 210 195 722
Total operating
expenses 69,451 55,101 198,505 161,900
Loss from operations (42,626) (31,561) (114,285) (93,001)
Other income (expense):
Interest income and
other, net 2,908 1,889 9,786 5,800
Interest expense (970) (1,071) (3,001) (3,943)
Gain on the sale of
business 18,808 -- 18,808 --
Total other income 20,746 818 25,593 1,857
Loss before noncontrolling
interest in Symphony
Evolution, Inc. (21,880) (30,743) (88,692) (91,144)
Loss attributed to
noncontrolling interest
in Symphony Evolution,
Inc. 8,184 5,546 22,233 14,834
Net loss $(13,696) $(25,197) $(66,459) $(76,310)
Net loss per share,
basic and
diluted $(0.14) $(0.30) $(0.68) $(0.91)
Shares used in computing
basic and diluted net
loss per share 98,551 84,178 97,313 83,972
EXELIXIS, INC.
CONSOLIDATED BALANCE SHEET DATA
(in thousands)
September 30, December 31,
2007 2006 (1)
(unaudited)
Cash and cash equivalents and short-term and
long-term marketable securities (2) $297,616 $263,180
Working capital $173,542 $150,814
Total assets $420,291 $395,417
St
'/>"/>
SOURCE Exelixis, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation2.
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer3.
Exelixis Announces Closing of Public Offering of Common Stock4.
Exelixis Submits XL880 Diligence Report to GlaxoSmithKline5.
Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results